Cancer/Tumor Profiling Market by Technology (Immunoassay, Next-generation Sequencing (NGS), Insitu Hybridization, Mass, Spectrometry, PCR, Microarray, and Others) by Biomarker Type (Genomic Biomarkers, and Protein Biomarkers), Cancer Type (Breast Cancer,

Published Jan 01, 2024

Length 365 Pages

SKU # NMSC18455877

Description

Cancer/Tumor Profiling Market by Technology (Immunoassay, Next-generation Sequencing (NGS), Insitu Hybridization, Mass, Spectrometry, PCR, Microarray, and Others) by Biomarker Type (Genomic Biomarkers, and Protein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, and Others), and by Application (Research Application and Clinical Application) – Global Opportunity Analysis and Industry Forecast, 2024–2030

Cancer/Tumor Profiling Market was valued at USD 11.75 billion in 2023, and is slated to surpass USD 26.57 billion by 2030, owing to the advancement in technologies.

Cancer/ Tumor Profiling Market
Domain – Life Sciences & Healthcare
Sub Domain – Medical Devices

The Cancer /Tumor Profiling market size was valued at USD 11.75 billion in 2023 and is predicted to reach USD 26.57 billion by 2030, with a CAGR of 12.4% from 2024 to 2030.

The rise in global cancer incidents, due to malnutrition and unhealthy lifestyles, catalyzes the expansion of the market. For instance, the World Health Organization (WHO) in February 2022 declared cancer a leading global cause of death and recorded 10 million fatalities in 2020.

Additionally, the increasing prevalence of human papillomavirus (HPV), a significant contributor to cervical cancer, amplifies the demand for interventions. As of February 2022, the WHO reported cervical cancer as the fourth most prevalent cancer in women, with around 604,000 new cases and 342,000 deaths globally in 2020. This surge in cancer cases underscores the importance of advanced diagnostic tools, including tumor profiling, to comprehensively understand and treat the evolving cancer landscape. The growing necessity for precision medicine and personalized treatment plans becomes increasingly crucial in addressing the diverse genetic profiles of tumors, aligning with broader trends in the cancer or tumor Profiling market.

Moreover, the introduction of Liquid biopsy technologies is driving the growth of the cancer profiling market by providing a non-invasive and real-time approach to monitoring tumor dynamics. The ability to detect minimal residual disease and emerging mutations early allows for timely intervention, aligning with the trend toward early detection in cancer care. These technologies offer a comprehensive view of tumor heterogeneity, aiding in the development of personalized and targeted therapeutic strategies. The convenience and accessibility, provided by liquid biopsies contribute significantly to the increasing demand for cancer profiling services.

However, the high cost associated with implementing advanced profiling technologies restrains the growth of the Cancer/ tumor profiling market. On the contrary, the integration of the Artificial Intelligence (AI) into cancer or tumor profiling represents a transformative leap in healthcare, presenting numerous growth opportunities

Segment Overview
The global Cancer/tumor profiling Market is segmented on the basis of technology, biomarker type, Cancer Type, Application, and region.
 By technology the market is classified into immunoassay, next-generation sequencing (NGS), insitu hybridization, mass, spectrometry, PCR, microarray, and others.
 By biomarker type, the market is segmented into genomic biomarkers and protein biomarkers.
 By cancer type, the market is categorized into breast cancer, lung cancer, colorectal cancer, and others.
 Region-wise, the market is segmented into North America, Europe, Asia-Pacific, and the rest of the world (RoW).

Regional Analysis
North America holds the dominant share of the market
North America holds the predominant market share in the field of Cancer or Tumor Profiling and is anticipated to maintain this dominance throughout the forecast period. The region experiences a rise in cancer cases due to elevated alcohol consumption and smoking habits, which in turn boost the market growth. In 2021, the United States alone witnessed 1.9 million new cancer diagnoses and 608,570 cancer-related deaths, as reported by the American Cancer Society.

The presence of key players such as Caris Life Sciences, Thermo Fisher Scientific Inc, Guardant Health, NeoGenomics Laboratories, and others further reinforces North America's significant position in the Cancer or Tumor Profiling market. These industry leaders, headquartered in North America, play a crucial role by providing state-of-the-art technologies, comprehensive molecular profiling services, and innovative diagnostic solutions. The robust infrastructure, substantial investments in research and development, and strategic collaborations within the region solidify North America as a central hub for advancements in cancer diagnostics and personalized medicine.

Key Market Players
The key players in the Cancer/tumor profiling Market include companies such as:
• Lucence Health Inc.
• F. Hoffmann-La Roche Ltd
• Caris Life Sciences
• ACT Genomics Co., Ltd.
• Thermo Fisher Scientific Inc.
• Strand Life Sciences
• IMB Dx, Inc.
• Illumina, Inc.
• Guardant Health
• QIAGEN
• Ribomed Biotechnologies Inc.
• HTG Molecular Diagnostics, Inc.
• NanoString
• NeoGenomics Laboratories
• Exact Sciences Corporation
• Others

Recent Developments
May 2023
Lucence Health Inc. introduced its revolutionary multi-cancer early detection (MCED) blood test, LucenceINSIGHT. It is the first MCED test introduced globally, and is a ctDNA-based liquid biopsy test capable of screening for 10 common cancers in a single blood draw.

May 2023
Pfizer and Thermo Fisher Scientific Inc. collaborated to enhance local accessibility to next-generation sequencing (NGS)-based testing for individuals diagnosed with lung and breast cancer. This strategic agreement underscores a shared commitment to advancing cancer profiling capabilities, particularly in the context of NGS technologies, which play a pivotal role in molecular diagnostics for these prevalent cancer types.

June 2023
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), in partnership with Exact Sciences, Guardant Health, Illumina, MSD, and Novartis, introduced the European Coalition for Access to Comprehensive Genomic Profiling (ECGP) within the cancer profiling market. The primary objective of this coalition is to elevate cancer care standards by advocating for heightened routine clinical access and reimbursement of CGP throughout Europe.

June 2022
Caris Life Sciences (Caris) introduced Caris Discovery a versatile discovery engine designed to combat cancer. This engine identifies new drug targets by combining unique capabilities, such as analyzing primary patient tissue and utilizing a proprietary aptamer-based proteomic profiling platform. Caris Discovery aims to contribute to the fight against cancer through innovative approaches to identifying potential therapeutic targets.

October 2021
F. Hoffmann-La Roche Ltd introduced the AVENIO Tumour Tissue Comprehensive Genomic Profiling (CGP) Kit, a novel genomic profiling tool that enables cancer researchers to analyze tumors locally, eliminating the need to send tissue samples to centralized laboratories. This kit was developed in collaboration with Roche Unit Foundation Medicine, a molecular information specialist whose products assist doctors in matching patients with suitable therapies and clinical trials.

KEY BENEFITS
• The Cancer/tumor profiling market report provides a quantitative analysis of the current market and estimations from 2024 to 2030. This analysis assists in identifying the prevailing market opportunities.
• The study comprises a detailed analysis of the Cancer/tumor profiling market trends, including current and future trends to depict prevalent investment pockets in the market.
• The information related to key drivers, restraints, and opportunities and their impact on the Cancer/tumor profiling market is provided in the report.
• The competitive analysis of the market players along with their market share in the Cancer/tumor profiling market is provided in the report.
• The SWOT analysis and Porter’s Five Forces model are elaborated in the report.
• The value chain analysis in the market study provides a clear picture of the role of stakeholders.

1 Introduction: 1.1 Report Description; 1.2 Research Methodology; 1.2.1 Secondary Research; 1.2.2 Data Analysis Framework; 1.2.3 Market Size Estimation; 1.2.4 Forecasting; 1.2.5 Primary Research And Data Validation
2 Cancer Tumor Profiling Market – Executive Summary: 2.1. Market Snapshot, 2023 - 2030, Million Usd
3 Porter’s Five Force Model Analysis: 3.1 Bargaining Power Of Suppliers; 3.2 Bargaining Power Of Buyers; 3.3 Degree Of Competition; 3.4 Threat Of Substitute; 3.5 Threat Of New Entrants
4 Market Share Analysis: 4.1 Market Share Analysis Of Top Providers, 2023
5 Market Dynamics: 5.1 Growth Drivers; 5.1.1 Driver 1; 5.1.2 Driver 2; 5.1.3 Driver 3; 5.1.4 Driver 4; 5.2 Challenges; 5.2.1 Challenge 1; 5.2.2 Challenge 2; 5.2.3 Challenge 3; 5.2.4 Challenge 4; 5.3 Opportunities; 5.3.1 Opportunity 1; 5.3.2 Opportunity 2
6 Global Cancer Tumor Profiling Market By Technology: 6.1 Overview; 6.2 Immunoassay; 6.2.1 Immunoassay Market, By Region; 6.2.1.1 North America Immunoassay Market, By Country; 6.2.1.2 Europe Immunoassay Market, By Country; 6.2.1.3 Asia-pacific Immunoassay Market, By Country; 6.2.1.4 Rest Of The World Immunoassay Market, By Country; 6.3 Ngs; 6.3.1 Ngs Market, By Region; 6.3.1.1 North America Ngs Market, By Country; 6.3.1.2 Europe Ngs Market, By Country; 6.3.1.3 Asia-pacific Ngs Market, By Country; 6.3.1.4 Rest Of The World Ngs Market, By Country; 6.4 Insitu Hybridization; 6.4.1 Insitu Hybridization Market, By Region; 6.4.1.1 North America Insitu Hybridization Market, By Country; 6.4.1.2 Europe Insitu Hybridization Market, By Country; 6.4.1.3 Asia-pacific Insitu Hybridization Market, By Country; 6.4.1.4 Rest Of The World Insitu Hybridization Market, By Country; 6.5 Mass; 6.5.1 Mass Market, By Region; 6.5.1.1 North America Mass Market, By Country; 6.5.1.2 Europe Mass Market, By Country; 6.5.1.3 Asia-pacific Mass Market, By Country; 6.5.1.4 Rest Of The World Mass Market, By Country; 6.6 Spectrometry; 6.6.1 Spectrometry Market, By Region; 6.6.1.1 North America Spectrometry Market, By Country; 6.6.1.2 Europe Spectrometry Market, By Country; 6.6.1.3 Asia-pacific Spectrometry Market, By Country; 6.6.1.4 Rest Of The World Spectrometry Market, By Country; 6.7 Pcr; 6.7.1 Pcr Market, By Region; 6.7.1.1 North America Pcr Market, By Country; 6.7.1.2 Europe Pcr Market, By Country; 6.7.1.3 Asia-pacific Pcr Market, By Country; 6.7.1.4 Rest Of The World Pcr Market, By Country; 6.8 Microarray; 6.8.1 Microarray Market, By Region; 6.8.1.1 North America Microarray Market, By Country; 6.8.1.2 Europe Microarray Market, By Country; 6.8.1.3 Asia-pacific Microarray Market, By Country; 6.8.1.4 Rest Of The World Microarray Market, By Country; 6.9 Others; 6.9.1 Others Market, By Region; 6.9.1.1 North America Others Market, By Country; 6.9.1.2 Europe Others Market, By Country; 6.9.1.3 Asia-pacific Others Market, By Country; 6.9.1.4 Rest Of The World Others Market, By Country
7 Global Cancer Tumor Profiling Market By Biomarker Type: 7.1 Overview; 7.2 Genomic Biomarkers; 7.2.1 Genomic Biomarkers Market, By Region; 7.2.1.1 North America Genomic Biomarkers Market, By Country; 7.2.1.2 Europe Genomic Biomarkers Market, By Country; 7.2.1.3 Asia-pacific Genomic Biomarkers Market, By Country; 7.2.1.4 Rest Of The World Genomic Biomarkers Market, By Country; 7.3 Protein Biomarkers; 7.3.1 Protein Biomarkers Market, By Region; 7.3.1.1 North America Protein Biomarkers Market, By Country; 7.3.1.2 Europe Protein Biomarkers Market, By Country; 7.3.1.3 Asia-pacific Protein Biomarkers Market, By Country; 7.3.1.4 Rest Of The World Protein Biomarkers Market, By Country
8 Global Cancer Tumor Profiling Market By Cancer Type: 8.1 Overview; 8.2 Breast Cancer; 8.2.1 Breast Cancer Market, By Region; 8.2.1.1 North America Breast Cancer Market, By Country; 8.2.1.2 Europe Breast Cancer Market, By Country; 8.2.1.3 Asia-pacific Breast Cancer Market, By Country; 8.2.1.4 Rest Of The World Breast Cancer Market, By Country; 8.3 Lung Cancer; 8.3.1 Lung Cancer Market, By Region; 8.3.1.1 North America Lung Cancer Market, By Country; 8.3.1.2 Europe Lung Cancer Market, By Country; 8.3.1.3 Asia-pacific Lung Cancer Market, By Country; 8.3.1.4 Rest Of The World Lung Cancer Market, By Country; 8.4 Colorectal Cancer; 8.4.1 Colorectal Cancer Market, By Region; 8.4.1.1 North America Colorectal Cancer Market, By Country; 8.4.1.2 Europe Colorectal Cancer Market, By Country; 8.4.1.3 Asia-pacific Colorectal Cancer Market, By Country; 8.4.1.4 Rest Of The World Colorectal Cancer Market, By Country; 8.5 Others; 8.5.1 Others Market, By Region; 8.5.1.1 North America Others Market, By Country; 8.5.1.2 Europe Others Market, By Country; 8.5.1.3 Asia-pacific Others Market, By Country; 8.5.1.4 Rest Of The World Others Market, By Country
9 Global Cancer Tumor Profiling Market By Application: 9.1 Overview; 9.2 Research Application; 9.2.1 Research Application Market, By Region; 9.2.1.1 North America Research Application Market, By Country; 9.2.1.2 Europe Research Application Market, By Country; 9.2.1.3 Asia-pacific Research Application Market, By Country; 9.2.1.4 Rest Of The World Research Application Market, By Country; 9.3 Clinical Application; 9.3.1 Clinical Application Market, By Region; 9.3.1.1 North America Clinical Application Market, By Country; 9.3.1.2 Europe Clinical Application Market, By Country; 9.3.1.3 Asia-pacific Clinical Application Market, By Country; 9.3.1.4 Rest Of The World Clinical Application Market, By Country
10 Global Cancer Tumor Profiling Market, By Region: 10.1 Overview; 10.2 North America; 10.2.1 North America Cancer Tumor Profiling Market, By Technology; 10.2.2 North America Cancer Tumor Profiling Market, By Biomarker Type; 10.2.3 North America Cancer Tumor Profiling Market, By Cancer Type; 10.2.4 North America Cancer Tumor Profiling Market, By Application; 10.2.5 North America Cancer Tumor Profiling Market, By Country; 10.2.5.1 United States; 10.2.5.1.1 United States Cancer Tumor Profiling Market, By Technology; 10.2.5.1.2 United States Cancer Tumor Profiling Market, By Biomarker Type; 10.2.5.1.3 United States Cancer Tumor Profiling Market, By Cancer Type; 10.2.5.1.4 United States Cancer Tumor Profiling Market, By Application; 10.2.5.2 Canada; 10.2.5.2.1 Canada Cancer Tumor Profiling Market, By Technology; 10.2.5.2.2 Canada Cancer Tumor Profiling Market, By Biomarker Type; 10.2.5.2.3 Canada Cancer Tumor Profiling Market, By Cancer Type; 10.2.5.2.4 Canada Cancer Tumor Profiling Market, By Application; 10.2.5.3 Mexico; 10.2.5.3.1 Mexico Cancer Tumor Profiling Market, By Technology; 10.2.5.3.2 Mexico Cancer Tumor Profiling Market, By Biomarker Type; 10.2.5.3.3 Mexico Cancer Tumor Profiling Market, By Cancer Type; 10.2.5.3.4 Mexico Cancer Tumor Profiling Market, By Application; 10.3 Europe; 10.3.1 Europe Cancer Tumor Profiling Market, By Technology; 10.3.2 Europe Cancer Tumor Profiling Market, By Biomarker Type; 10.3.3 Europe Cancer Tumor Profiling Market, By Cancer Type; 10.3.4 Europe Cancer Tumor Profiling Market, By Application; 10.3.5 Europe Cancer Tumor Profiling Market, By Country; 10.3.5.1 Germany; 10.3.5.1.1 Germany Cancer Tumor Profiling Market, By Technology; 10.3.5.1.2 Germany Cancer Tumor Profiling Market, By Biomarker Type; 10.3.5.1.3 Germany Cancer Tumor Profiling Market, By Cancer Type; 10.3.5.1.4 Germany Cancer Tumor Profiling Market, By Application; 10.3.5.2 France; 10.3.5.2.1 France Cancer Tumor Profiling Market, By Technology; 10.3.5.2.2 France Cancer Tumor Profiling Market, By Biomarker Type; 10.3.5.2.3 France Cancer Tumor Profiling Market, By Cancer Type; 10.3.5.2.4 France Cancer Tumor Profiling Market, By Application; 10.3.5.3 Italy; 10.3.5.3.1 Italy Cancer Tumor Profiling Market, By Technology; 10.3.5.3.2 Italy Cancer Tumor Profiling Market, By Biomarker Type; 10.3.5.3.3 Italy Cancer Tumor Profiling Market, By Cancer Type; 10.3.5.3.4 Italy Cancer Tumor Profiling Market, By Application; 10.3.5.4 Spain; 10.3.5.4.1 Spain Cancer Tumor Profiling Market, By Technology; 10.3.5.4.2 Spain Cancer Tumor Profiling Market, By Biomarker Type; 10.3.5.4.3 Spain Cancer Tumor Profiling Market, By Cancer Type; 10.3.5.4.4 Spain Cancer Tumor Profiling Market, By Application; 10.3.5.5 United Kingdom; 10.3.5.5.1 United Kingdom Cancer Tumor Profiling Market, By Technology; 10.3.5.5.2 United Kingdom Cancer Tumor Profiling Market, By Biomarker Type; 10.3.5.5.3 United Kingdom Cancer Tumor Profiling Market, By Cancer Type; 10.3.5.5.4 United Kingdom Cancer Tumor Profiling Market, By Application; 10.3.5.6 Rest Of Europe; 10.3.5.6.1 Rest Of Europe Cancer Tumor Profiling Market, By Technology; 10.3.5.6.2 Rest Of Europe Cancer Tumor Profiling Market, By Biomarker Type; 10.3.5.6.3 Rest Of Europe Cancer Tumor Profiling Market, By Cancer Type; 10.3.5.6.4 Rest Of Europe Cancer Tumor Profiling Market, By Application; 10.4 Asia-pacific; 10.4.1 Asia-pacific Cancer Tumor Profiling Market, By Technology; 10.4.2 Asia-pacific Cancer Tumor Profiling Market, By Biomarker Type; 10.4.3 Asia-pacific Cancer Tumor Profiling Market, By Cancer Type; 10.4.4 Asia-pacific Cancer Tumor Profiling Market, By Application; 10.4.5 Asia-pacific Cancer Tumor Profiling Market, By Country; 10.4.5.1 Australia; 10.4.5.1.1 Australia Cancer Tumor Profiling Market, By Technology; 10.4.5.1.2 Australia Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.1.3 Australia Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.1.4 Australia Cancer Tumor Profiling Market, By Application; 10.4.5.2 China; 10.4.5.2.1 China Cancer Tumor Profiling Market, By Technology; 10.4.5.2.2 China Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.2.3 China Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.2.4 China Cancer Tumor Profiling Market, By Application; 10.4.5.3 India; 10.4.5.3.1 India Cancer Tumor Profiling Market, By Technology; 10.4.5.3.2 India Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.3.3 India Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.3.4 India Cancer Tumor Profiling Market, By Application; 10.4.5.4 Japan; 10.4.5.4.1 Japan Cancer Tumor Profiling Market, By Technology; 10.4.5.4.2 Japan Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.4.3 Japan Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.4.4 Japan Cancer Tumor Profiling Market, By Application; 10.4.5.5 South Korea; 10.4.5.5.1 South Korea Cancer Tumor Profiling Market, By Technology; 10.4.5.5.2 South Korea Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.5.3 South Korea Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.5.4 South Korea Cancer Tumor Profiling Market, By Application; 10.4.5.6 Indonesia; 10.4.5.6.1 Indonesia Cancer Tumor Profiling Market, By Technology; 10.4.5.6.2 Indonesia Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.6.3 Indonesia Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.6.4 Indonesia Cancer Tumor Profiling Market, By Application; 10.4.5.7 Singapore; 10.4.5.7.1 Singapore Cancer Tumor Profiling Market, By Technology; 10.4.5.7.2 Singapore Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.7.3 Singapore Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.7.4 Singapore Cancer Tumor Profiling Market, By Application; 10.4.5.8 Vietnam; 10.4.5.8.1 Vietnam Cancer Tumor Profiling Market, By Technology; 10.4.5.8.2 Vietnam Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.8.3 Vietnam Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.8.4 Vietnam Cancer Tumor Profiling Market, By Application; 10.4.5.9 Rest Of Asia-pacific; 10.4.5.9.1 Rest Of Asia-pacific Cancer Tumor Profiling Market, By Technology; 10.4.5.9.2 Rest Of Asia-pacific Cancer Tumor Profiling Market, By Biomarker Type; 10.4.5.9.3 Rest Of Asia-pacific Cancer Tumor Profiling Market, By Cancer Type; 10.4.5.9.4 Rest Of Asia-pacific Cancer Tumor Profiling Market, By Application; 10.5 Rest Of The World; 10.5.1 Rest Of The World Cancer Tumor Profiling Market, By Technology; 10.5.2 Rest Of The World Cancer Tumor Profiling Market, By Biomarker Type; 10.5.3 Rest Of The World Cancer Tumor Profiling Market, By Cancer Type; 10.5.4 Rest Of The World Cancer Tumor Profiling Market, By Application; 10.5.5 Rest Of The World Cancer Tumor Profiling Market, By Country; 10.5.5.1 Latin America; 10.5.5.1.1 Latin America Cancer Tumor Profiling Market, By Technology; 10.5.5.1.2 Latin America Cancer Tumor Profiling Market, By Biomarker Type; 10.5.5.1.3 Latin America Cancer Tumor Profiling Market, By Cancer Type; 10.5.5.1.4 Latin America Cancer Tumor Profiling Market, By Application; 10.5.5.2 Middle East; 10.5.5.2.1 Middle East Cancer Tumor Profiling Market, By Technology; 10.5.5.2.2 Middle East Cancer Tumor Profiling Market, By Biomarker Type; 10.5.5.2.3 Middle East Cancer Tumor Profiling Market, By Cancer Type; 10.5.5.2.4 Middle East Cancer Tumor Profiling Market, By Application; 10.5.5.3 Africa; 10.5.5.3.1 Africa Cancer Tumor Profiling Market, By Technology; 10.5.5.3.2 Africa Cancer Tumor Profiling Market, By Biomarker Type; 10.5.5.3.3 Africa Cancer Tumor Profiling Market, By Cancer Type; 10.5.5.3.4 Africa Cancer Tumor Profiling Market, By Application
11 Company Profiles: 11.1 Lucence Health Inc.; 11.1.1 Company Overview; 11.1.2 Company Snapshot; 11.1.3 Operating Business Segments; 11.1.4 Product Portfolio; 11.1.5 Business Performance; 11.1.6 Business Segments; 11.1.7 Geographic Segments; 11.1.8 Key Strategic Moves And Development; 11.1.9 Primary Market Competitors; 11.2 F. Hoffmann-la Roche Ltd.; 11.2.1 Company Overview; 11.2.2 Company Snapshot; 11.2.3 Operating Business Segments; 11.2.4 Product Portfolio; 11.2.5 Business Performance; 11.2.6 Business Segments; 11.2.7 Geographic Segments; 11.2.8 Key Strategic Moves And Development; 11.2.9 Primary Market Competitors; 11.3 Caris Life Sciences; 11.3.1 Company Overview; 11.3.2 Company Snapshot; 11.3.3 Operating Business Segments; 11.3.4 Product Portfolio; 11.3.5 Business Performance; 11.3.6 Business Segments; 11.3.7 Geographic Segments; 11.3.8 Key Strategic Moves And Development; 11.3.9 Primary Market Competitors; 11.4 Act Genomics Co., Ltd; 11.4.1 Company Overview; 11.4.2 Company Snapshot; 11.4.3 Operating Business Segments; 11.4.4 Product Portfolio; 11.4.5 Business Performance; 11.4.6 Business Segments; 11.4.7 Geographic Segments; 11.4.8 Key Strategic Moves And Development; 11.4.9 Primary Market Competitors; 11.5 Thermo Fisher Scientific Inc.; 11.5.1 Company Overview; 11.5.2 Company Snapshot; 11.5.3 Operating Business Segments; 11.5.4 Product Portfolio; 11.5.5 Business Performance; 11.5.6 Business Segments; 11.5.7 Geographic Segments; 11.5.8 Key Strategic Moves And Development; 11.5.9 Primary Market Competitors; 11.6 Strand Life Sciences; 11.6.1 Company Overview; 11.6.2 Company Snapshot; 11.6.3 Operating Business Segments; 11.6.4 Product Portfolio; 11.6.5 Business Performance; 11.6.6 Business Segments; 11.6.7 Geographic Segments; 11.6.8 Key Strategic Moves And Development; 11.6.9 Primary Market Competitors; 11.7 Imb Dx, Inc.; 11.7.1 Company Overview; 11.7.2 Company Snapshot; 11.7.3 Operating Business Segments; 11.7.4 Product Portfolio; 11.7.5 Business Performance; 11.7.6 Business Segments; 11.7.7 Geographic Segments; 11.7.8 Key Strategic Moves And Development; 11.7.9 Primary Market Competitors; 11.8 Illumina, Inc.; 11.8.1 Company Overview; 11.8.2 Company Snapshot; 11.8.3 Operating Business Segments; 11.8.4 Product Portfolio; 11.8.5 Business Performance; 11.8.6 Business Segments; 11.8.7 Geographic Segments; 11.8.8 Key Strategic Moves And Development; 11.8.9 Primary Market Competitors; 11.9 Guardant Health; 11.9.1 Company Overview; 11.9.2 Company Snapshot; 11.9.3 Operating Business Segments; 11.9.4 Product Portfolio; 11.9.5 Business Performance; 11.9.6 Business Segments; 11.9.7 Geographic Segments; 11.9.8 Key Strategic Moves And Development; 11.9.9 Primary Market Competitors; 11.10 Qiagen; 11.10.1 Company Overview; 11.10.2 Company Snapshot; 11.10.3 Operating Business Segments; 11.10.4 Product Portfolio; 11.10.5 Business Performance; 11.10.6 Business Segments; 11.10.7 Geographic Segments; 11.10.8 Key Strategic Moves And Development; 11.10.9 Primary Market Competitors; 11.11 Ribomed Biotechnologies Inc.; 11.11.1 Company Overview; 11.11.2 Company Snapshot; 11.11.3 Operating Business Segments; 11.11.4 Product Portfolio; 11.11.5 Business Performance; 11.11.6 Business Segments; 11.11.7 Geographic Segments; 11.11.8 Key Strategic Moves And Development; 11.11.9 Primary Market Competitors; 11.12 Htg Molecular Diagnostics, Inc.; 11.12.1 Company Overview; 11.12.2 Company Snapshot; 11.12.3 Operating Business Segments; 11.12.4 Product Portfolio; 11.12.5 Business Performance; 11.12.6 Business Segments; 11.12.7 Geographic Segments; 11.12.8 Key Strategic Moves And Development; 11.12.9 Primary Market Competitors; 11.13 Nanostring; 11.13.1 Company Overview; 11.13.2 Company Snapshot; 11.13.3 Operating Business Segments; 11.13.4 Product Portfolio; 11.13.5 Business Performance; 11.13.6 Business Segments; 11.13.7 Geographic Segments; 11.13.8 Key Strategic Moves And Development; 11.13.9 Primary Market Competitors; 11.14 Neogenomics Laboratories; 11.14.1 Company Overview; 11.14.2 Company Snapshot; 11.14.3 Operating Business Segments; 11.14.4 Product Portfolio; 11.14.5 Business Performance; 11.14.6 Business Segments; 11.14.7 Geographic Segments; 11.14.8 Key Strategic Moves And Development; 11.14.9 Primary Market Competitors; 11.15 Exact Sciences Corporation (Genomic Health, Inc.); 11.15.1 Company Overview; 11.15.2 Company Snapshot; 11.15.3 Operating Business Segments; 11.15.4 Product Portfolio; 11.15.5 Business Performance; 11.15.6 Business Segments; 11.15.7 Geographic Segments; 11.15.8 Key Strategic Moves And Development; 11.15.9 Primary Market Competitors

Pricing

Currency Rates

Single User Email from Publisher $3,975
Global Site License Email from Publisher $6,975

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now